Researchers used base editing — a type of CRISPR technology — to create a cell-therapy product with potent activity in children with relapsed T-ALL.

Georgiadis C, Rasaiyaah J, Gkazi SA, et al. Base-edited CAR T cells for combinational therapy against T cell malignancies. Leukemia 2021;35:3466-3481. Crossref. PubMed. Web of Science.

Three young patients with relapsed T-cell leukemia have now been treated with base-edited T-cells, as part of a 'bench-to-bedside' collaboration between UCL and Great Ormond Street Hospital for ...